+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antiobesity Drugs Global Market Report 2020

  • ID: 4855986
  • Report
  • November 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals
  • Zafgen
  • MORE
Antiobesity Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global antiobesity drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the antiobesity drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antiobesity Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Drug Class: Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs 2) By Type: Prescription Drugs (Rx), OTC Drugs 3) By Medication: Monotherapies, Polytherapies
  • Companies Mentioned: F. Hoffmann-La Roche AG, , GlaxoSmithKline PLC, , Boehringer Ingelheim GmbH, , Pfizer Inc.,, Merck & Co. Inc.,
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals
  • Zafgen
  • MORE
1. Executive Summary

2. Anti-obesity Drugs Market Characteristics

3. Anti-obesity Drugs Market Size And Growth
3.1. Global Anti-obesity Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Anti-obesity Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Anti-obesity Drugs Market Segmentation
4.1. Global Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Peripherally acting anti obesity drugs Centrally acting anti obesity drugs
4.2. Global Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Prescription Drugs (Rx) OTC Drugs
4.3. Global Anti-obesity Drugs Market, Segmentation By Medication, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Monotherapies Polytherapies
5. Anti-obesity Drugs Market Regional And Country Analysis
5.1. Global Anti-obesity Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Anti-obesity Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Anti-obesity Drugs Market
6.1. Asia-Pacific Anti-obesity Drugs Market Overview
6.2. Asia-Pacific Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Anti-obesity Drugs Market
7.1. China Anti-obesity Drugs Market Overview
7.2. China Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Anti-obesity Drugs Market
8.1. India Anti-obesity Drugs Market Overview
8.2. India Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Anti-obesity Drugs Market
9.1. Japan Anti-obesity Drugs Market Overview
9.2. Japan Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Anti-obesity Drugs Market
10.1. Australia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Anti-obesity Drugs Market
11.1. Indonesia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Anti-obesity Drugs Market
12.1. South Korea Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Anti-obesity Drugs Market
13.1. Western Europe Anti-obesity Drugs Market Overview
13.2. Western Europe Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Anti-obesity Drugs Market
14.1. UK Anti-obesity Drugs Market Overview
14.2. UK Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Anti-obesity Drugs Market
15.1. Germany Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Anti-obesity Drugs Market
16.4. France Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Anti-obesity Drugs Market
17.1. Eastern Europe Anti-obesity Drugs Market Overview
17.2. Eastern Europe Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Anti-obesity Drugs Market
18.1. Russia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Anti-obesity Drugs Market
19.1. North America Anti-obesity Drugs Market Overview
19.2. North America Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Anti-obesity Drugs Market
20.1. USA Anti-obesity Drugs Market Overview
20.2. USA Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Anti-obesity Drugs Market
21.1. South America Anti-obesity Drugs Market Overview
21.2. South America Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Anti-obesity Drugs Market
22.1. Brazil Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Anti-obesity Drugs Market
23.1. Middle East Anti-obesity Drugs Market Overview
23.2. Middle East Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Anti-obesity Drugs Market
24.1. Africa Anti-obesity Drugs Market Overview
24.2. Africa Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Anti-obesity Drugs Market Competitive Landscape And Company Profiles
25.1. Anti-obesity Drugs Market Competitive Landscape
25.2. Anti-obesity Drugs Market Company Profiles
25.2.1. F. Hoffmann-La Roche AG,
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. GlaxoSmithKline PLC,
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Boehringer Ingelheim GmbH,
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Pfizer Inc.,
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Merck & Co. Inc.,
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Anti-obesity Drugs Market

27. Anti-obesity Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Anti-obesity Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals
  • Zafgen
  • MORE
The anti-obesity drugs market consists of sales of anti-obesity drugs and related services. This industry includes establishments that produce pharmacological agents that reduce or control overweight.

The global antiobesity market was valued at about $1.3 billion in 2018 and is expected to grow to $3.44 billion at a CAGR of 27.5% through 2022.

The anti-obesity drugs market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa. The North American market is the largest market for anti-obesity drugs and is expected to continue to be the largest market during the forecast period.

Obesity is a major public health concern globally. Globally, prevalence rate of obesity is increasing every year. According to WHO, in 2016, more than 1.9 billion adults over the age of 18 years were overweight of which over 650 million were obese. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity and lack of awareness on the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving market growth.

Obesity is a major health problem worldwide which is caused from leading a sedentary lifestyle and consumption of unhealthy food. Though various anti-obesity drugs have been approved and are available in the USA, European Union, Australia, and Japan to treat obesity and overweight. It has been observed that these drugs have various adverse effects on patients undergoing treatment for obesity. Adverse effects include low blood pressure and blood glucose, incontinence, insomnia, nausea, diarrhea and others. For instance, Sibutramine and its combination drugs sold under various brands was recalled in various countries due to various side effects including heart attack in consumers. These factors restraint the growth of anti-obesity drugs market.

Pharmaceutical industry is witnessing an increase in the number of mergers and acquisition among companies developing drugs for metabolic disorders such as obesity, diabetes and others. This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market. For instance, in 2018, Evotec AG and Novo Nordisk entered into a strategic alliance to be able to discover and develop drug molecules to treat metabolic disorders including obesity, diabetes and other associated disorders.

Major players in the market are F. Hoffmann-La Roche AG, , GlaxoSmithKline PLC, , Boehringer Ingelheim GmbH, and Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Takeda Pharmaceuticals Company Limited
  • Eisai Co. Ltd.
  • Novo Nordisk A/S
  • Zafgen
  • Rhythm Pharmaceuticals
  • Zydus Cadila
  • Norgine B.V.
  • Vivus Therapeutics
  • Arena Pharmaceuticals Inc.
  • Orexigen Therapeutics Inc.
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll